Colchicine-Update on mechanisms of action and therapeutic uses

Seminars in Arthritis and Rheumatism

Volumn 45, Issue 3, 2015, Pages 341-350

  Leung, Ying Ying ^a,b   Yao Hui, Laura Li ^a   Kraus, Virginia B ^c  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Colchicines; Inflammation; Mechanism of action; Pharmacokinetics; Therapeutic use

Indexed keywords

COLCHICINE; CRYOPYRIN; PLACEBO; PURINERGIC P2X2 RECEPTOR; PURINERGIC P2X7 RECEPTOR; SUPEROXIDE; TUBULIN; ANTIGOUT AGENT;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ALCOHOL LIVER CIRRHOSIS; ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; APHTHOUS STOMATITIS; APLASTIC ANEMIA; ARTHRITIS; ATHEROSCLEROSIS; BEHCET DISEASE; BLOOD DYSCRASIA; BONE MARROW SUPPRESSION; CEREBROVASCULAR ACCIDENT; CHRONIC URTICARIA; CORONARY ARTERY DISEASE; DENDRITIC CELL; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; FAMILIAL MEDITERRANEAN FEVER; GASTROINTESTINAL SYMPTOM; GOUT; GRANULOCYTOPENIA; HEART FAILURE; HUMAN; IMMUNOMODULATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; KIDNEY FIBROSIS; KNEE OSTEOARTHRITIS; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; LEUKOPENIA; LIVER CIRRHOSIS; LIVER FIBROSIS; LOW DRUG DOSE; MACROPHAGE; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; MYOPATHY; NAUSEA; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OSTEOARTHRITIS; PANCYTOPENIA; PERICARDITIS; PERITONEAL FIBROSIS; POSTPERICARDIOTOMY SYNDROME; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RHABDOMYOLYSIS; SORE THROAT; SUPPURATIVE HIDRADENITIS; THROMBOCYTOPENIA; VOMITING; ARTHRITIS, GOUTY; METABOLISM;

ARTHRITIS, GOUTY; COLCHICINE; GOUT; GOUT SUPPRESSANTS; HUMANS; TUBULIN;

EID: 84955730816     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2015.06.013     Document Type: Review

References (106)

1. Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep 2008, 10:218-227.
2. Terkeltaub R.A. Colchicine update: 2008. Semin Arthritis Rheum 2009, 38:411-419.
3. Bhattacharyya B., Panda D., Gupta S., Banerjee M. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med Res Rev 2008, 28:155-183.
4. Massarotti A., Coluccia A., Silvestri R., Sorba G., Brancale A. The tubulin colchicine domain: a molecular modeling perspective. ChemMedChem 2012, 7:33-42.
5. Charpentier M.S., Whipple R.A., Vitolo M.I., Boggs A.E., Slovic J., Thompson K.N., et al. Curcumin targets breast cancer stem-like cells with microtentacles that persist in mammospheres and promote reattachment. Cancer Res 2014, 74:1250-1260.
6. Meshki J., Douglas S.D., Hu M., Leeman S.E., Tuluc F. Substance P induces rapid and transient membrane blebbing in U373MG cells in a p21-activated kinase-dependent manner. PloS One 2011, 6:e25332.
7. Ganguly A., Yang H., Zhang H., Cabral F., Patel K.D. Microtubule dynamics control tail retraction in migrating vascular endothelial cells. Mol Cancer Ther 2013, 12:2837-2846.
8. Maldonado E.N., Patnaik J., Mullins M.R., Lemasters J.J. Free tubulin modulates mitochondrial membrane potential in cancer cells. Cancer Res 2010, 70:10192-10201.
9. Phelps P. Polymorphonuclear leukocyte motility in vitro: IV. Colchicine inhibition of chemotactic activity formation after phagocytosis of urate crystals. Arthritis Rheum 2008, 58(Suppl. 2):S25-S33.
10. McCarty D.J. Urate crystals, inflammation, and colchicine. Arthritis Rheum 2008, 58(Suppl. 2):S20-S24.
11. Ryckman C., McColl S.R., Vandal K., de Médicis R., Lussier A., Poubelle P.E., et al. Role of S100A8 and S100A9 in neutrophil recruitment in response to monosodium urate monohydrate crystals in the air-pouch model of acute gouty arthritis. Arthritis Rheum 2003, 48:2310-2320.
12. Gagné V., Marois L., Levesque J.M., Galarneau H., Lahoud M.H., Caminschi I., et al. Modulation of monosodium urate crystal-induced responses in neutrophils by the myeloid inhibitory C-type lectin-like receptor: potential therapeutic implications. Arthritis Res Ther 2013, 15:R73.
13. Asako H., Kubes P., Baethge B.A., Wolf R.E., Granger D.N. Colchicine and methotrexate reduce leukocyte adherence and emigration in rat mesenteric venules. Inflammation 1992, 16:45-56.
14. Cronstein B.N., Molad Y., Reibman J., Balakhane E., Levin R.I., Weissmann G., et al. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995, 96:994-1002.
15. Roberge C.J., Gaudry M., de Médicis R., Lussier A., Poubelle P.E., Naccache P.H., et al. Crystal-induced neutrophil activation. IV. Specific inhibition of tyrosine phosphorylation by colchicine. J Clin Invest 1993, 92:1722-1729.
16. Popa-Nita O., Marois L., Paré G., Naccache P.H. Crystal-induced neutrophil activation: X. Proinflammatory role of the tyrosine kinase Tec. Arthritis Rheum 2008, 58:1866-1876.
17. Paschke S., Weidner A.F., Paust T., Marti O., Beil M., Ben-Chetrit E., et al. Technical advance: inhibition of neutrophil chemotaxis by colchicine is modulated through viscoelastic properties of subcellular compartments. J Leukoc Biol 2013, 94:1091-1096.
18. Chia E.W., Grainger R., Harper J.L. Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: a rationale for use of low-dose colchicine. Br J Pharmacol 2008, 153:1288-1295.
19. + release and antioxidant system. J Membr Biol 2011, 244:113-120.
20. Martinon F., Pétrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
21. Misawa T., Takahama M., Kozaki T., Lee H., Zou J., Saitoh T., et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol 2013, 14:454-460.
22. Taskiran E.Z., Cetinkaya A., Balci-Peynircioglu B., Akkaya Y.Z., Yilmaz E. The effect of colchicine on pyrin and pyrin interacting proteins. J Cell Biochem 2012, 113:3536-3546.
23. Yu J.W., Farias A., Hwang I., Fernandes-Alnemri T., Alnemri E.S. Ribotoxic stress through p38 mitogen-activated protein kinase activates in vitro the human pyrin inflammasome. J Biol Chem 2013, 288:11378-11383.
24. Cronstein B.N., Sunkureddi P. Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. J Clin Rheumatol 2013, 19:19-29.
25. Fordham J.N., Kirwan J., Cason J., Currey H.L. Prolonged reduction in polymorphonuclear adhesion following oral colchicine. Ann Rheum Dis 1981, 40:605-608.
26. Pascual E., Castellano J.A. Treatment with colchicine decreases white cell counts in synovial fluid of asymptomatic knees that contain monosodium urate crystals. J Rheumatol 1992, 19:600-603.
27. Chae J.J., Wood G., Richard K., Jaffe H., Colburn N.T., Masters S.L., et al. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-κB through its N-terminal fragment. Blood 2008, 112:1794-1803.
28. Viktorov A.V., Yurkiv V.A. Albendazole and colchicine modulate LPS-induced secretion of inflammatory mediators by liver macrophages. Bull Exp Biol Med 2011, 151:683-685.
29. Takenouchi T., Iwamaru Y., Sugama S., Sato M., Hashimoto M., Kitani H., et al. Lysophospholipids and ATP mutually suppress maturation and release of IL-1 beta in mouse microglial cells using a Rho-dependent pathway. J Immunol 2008, 180:7827-7839.
30. Marques-da-Silva C., Chaves M.M., Castro N.G., Coutinho-Silva R., Guimaraes M.Z. Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor-expressing cells: implications for its therapeutic action. Br J Pharmacol 2011, 163:912-926.
31. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
32. Pelegrín P. Many ways to dilate the P2X7 receptor pore. Br J Pharmacol 2011, 163:908-911.
33. Mizumoto N., Gao J., Matsushima H., Ogawa Y., Tanaka H., Takashima A., et al. Discovery of novel immunostimulants by dendritic-cell-based functional screening. Blood 2005, 106:3082-3089.
34. Mizumoto N., Tanaka H., Matsushima H., Vishwanath M., Takashima A. Colchicine promotes antigen cross-presentation by murine dendritic cells. J Invest Dermatol 2007, 127:1543-1546.
35. Marin-Esteban V., Charron D., Gelin C., Mooney N. Chemotherapeutic agents targeting the tubulin cytoskeleton modify LPS-induced cytokine secretion by dendritic cells and increase antigen presentation. J Immunother 2010, 33:364-370.
36. Peachman K.K., Rao M., Palmer D.R., Zidanic M., Sun W., Alving C.R., et al. Functional microtubules are required for antigen processing by macrophages and dendritic cells. Immunol Lett 2004, 95:13-24.
37. Li C., Yang C.W., Ahn H.J., Kim W.Y., Park C.W., Park J.H., et al. Colchicine decreases apoptotic cell death in chronic cyclosporine nephrotoxicity. J Lab Clin Med 2002, 139:364-371.
38. Guan T., Gao B., Chen G., Chen X., Janssen M., Uttarwar L., et al. Colchicine attenuates renal injury in a model of hypertensive chronic kidney disease. Am J Physiol Renal Physiol 2013, 305:F1466-F1476.
39. Shu J.C., He Y.J., Lv X., Ye G.R., Wang L.X. Curcumin prevents liver fibrosis by inducing apoptosis and suppressing activation of hepatic stellate cells. J Nat Med 2009, 63:415-420.
40. Bozkurt D., Bicak S., Sipahi S., Taskin H., Hur E., Ertilav M., et al. The effects of colchicine on the progression and regression of encapsulating peritoneal sclerosis. Perit Dial Int 2008, 28(Suppl. 5):S53-S57.
41. Sandbo N., Ngam C., Torr E., Kregel S., Kach J., Dulin N., et al. Control of myofibroblast differentiation by microtubule dynamics through a regulated localization of mDia2. J Biol Chem 2013, 288:15466-15473.
42. Abanonu G.B., Daskin A., Akdogan M.F., Uyar S., Demirtunc R. Mean platelet volume and β-thromboglobulin levels in familial Mediterranean fever: effect of colchicine use?. Eur J Intern Med 2012, 23:661-664.
43. Terekeci H.M., Oktenli C., Ozgurtas T., Nalbant S., Top C., Celik S., et al. Increased asymmetric dimethylarginine levels in young men with familial Mediterranean fever (FMF): is it early evidence of interaction between inflammation and endothelial dysfunction in FMF?. J Rheumatol 2008, 35:2024-2029.
44. Atta H.M., El-Rehany M.A., Abdel Raheim S.R., Fouad R., A.M.Galal Colchicine inhibits intimal hyperplasia and leukocyte VEGF expression in dogs. J Surg Res 2008, 146:184-189.
45. Lee F.Y., Lu H.I., Zhen Y.Y., Leu S., Chen Y.L., Tsai T.H., et al. Benefit of combined therapy with nicorandil and colchicine in preventing monocrotaline-induced rat pulmonary arterial hypertension. Eur J Pharm Sci 2013, 50:372-384.
46. Huang C., Cen C., Wang C., Zhan H., Ding X. Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia. Lipids Health Dis 2014, 13:67.
47. Terkeltaub R.A., Furst D.E., Bennett K., Kook K.A., Crockett R.S., Davis M.W., et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010, 62:1060-1068.
48. U.S. Food and Drug Administration. Online, . Accessed 20.12.13. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174315.htm.
49. Terkeltaub R.A., Furst D.E., Digiacinto J.L., Kook K.A., Davis M.W. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum 2011, 63:2226-2237.
50. National Center for Biotechnology Information. Online, . Accessed 20.12.14. http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?chooseRs=coding&locusId=5243&mrna.
51. Ozen F., Silan C., Uludag A., Candan F., Silan F., Ozdemir S., et al. Association between ABCB1 (MDR1) gene 3435 C>T polymorphism and colchicine unresponsiveness of FMF patients. Ren Fail 2011, 33:899-903.
52. Tufan A., Babaoglu M.O., Akdogan A., Yasar U., Calguneri M., Kalyoncu U., et al. Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J Rheumatol 2007, 34:1540-1544.
53. Uludag A., Silan C., Atik S., Akurut C., Uludag A., Silan F., et al. Relationship between response to colchicine treatment and MDR1 polymorphism in familial Mediterranean fever patients. Genet Tes Mol Biomarkers 2014, 18:73-76.
54. Rustemoglu A., Gül Ü., Gümüş-Akay G., Gönül M., Yiğit S., Bozkurt N., et al. MDR1 gene polymorphisms may be associated with Behçet's disease and its colchicum treatment response. Gene 2012, 505:333-339.
55. Dogruer D., Tug E., Bes C., Soy M. Lack of an effect of CYP3A4 and MDR1 gene polymorphisms on colchicine pharmacogenetics in the treatment of Familial Mediterranean fever. Genet Mol Res 2013, 12:3521-3528.
56. Saricaoglu H., Yilmaz M., Karkucak M., Ozturk H.Z., Yakut T., Gulten T., et al. Investigation of ABCB1 gene polymorphism with colchicine response in Behçet's disease. Genet Mol Res 2011, 10:1-6.
57. Khanna D., Khanna P.P., Fitzgerald J.D., Singh M.K., Bae S., Neogi T., et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 2012, 64:1447-1461.
58. Hamburger M., Baraf H.S., Adamson T.C., Basile J., Bass L., Cole B., et al. 2011 Recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med 2011, 123(6 Suppl. 1):3-36.
59. Wortmann R.L., Macdonald P.A., Hunt B., Jackson R.L. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther 2010, 32:2386-2397.
60. Borstad G.C., Bryant L.R., Abel M.P., Scroggie D.A., Harris M.D., Alloway J.A., et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004, 31:2429-2432.
61. Acheson R.M., Collart A.B. New Haven survey of joint diseases. XVII. Relationship between some systemic characteristics and osteoarthrosis in a general population. Ann Rheum Dis 1975, 34:379-387.
62. Sun Y., Brenner H., Sauerland S., Günther K.P., Puhl W., Stürmer T., et al. Serum uric acid and patterns of radiographic osteoarthritis-the Ulm Osteoarthritis Study. Scand J Rheumatol 2000, 29:380-386.
63. Roddy E., Zhang W., Doherty M. Are joints affected by gout also affected by osteoarthritis?. Ann Rheum Dis 2007, 66:1374-1377.
64. Muehleman C., Li J., Aigner T., Rappoport L., Mattson E., Hirschmugl C., et al. Association between crystals and cartilage degeneration in the ankle. J Rheumatol 2008, 35:1108-1117.
65. Chhana A., Callon K.E., Pool B., Naot D., Gamble G.D., Dray M., et al. The effects of monosodium urate monohydrate crystals on chondrocyte viability and function: implications for development of cartilage damage in gout. J Rheumatol 2013, 40:2067-2074.
66. Denoble A.E., Huffman K.M., Stabler T.V., Kelly S.J., Hershfield M.S., McDaniel G.E., et al. Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation. Proc Natl Acad Sci U S A 2011, 108:2088-2093.
67. Das S.K., Mishra K., Ramakrishnan S., Srivastava R., Agarwal G.G., Singh R., et al. A randomized controlled trial to evaluate the slow-acting symptom modifying effects of a regimen containing colchicine in a subset of patients with osteoarthritis of the knee. Osteoarthritis Cartilage 2002, 10:247-252.
68. Das S.K., Ramakrishnan S., Mishra K., Srivastava R., Agarwal G.G., Singh R., et al. A randomized controlled trial to evaluate the slow-acting symptom-modifying effects of colchicine in osteoarthritis of the knee: a preliminary report. Arthritis Rheum 2002, 47:280-284.
69. Aran S., Malekzadeh S., Seifirad S. A double-blind randomized controlled trial appraising the symptom-modifying effects of colchicine on osteoarthritis of the knee. Clin Exp Rheumatol 2011, 29:513-518.
70. Leung Y.Y., Thumboo J., Wong B.S., Haaland B., Chowbay B., Chakraborty B., et al. Colchicine effectiveness in symptom and inflammation modification in knee osteoarthritis (COLKOA): study protocol for a randomized controlled trial. Trials 2015, 16:200.
71. Takeuchi M., Asukata Y., Kawagoe T., Ito N., Nishide T., Mizuki N., et al. Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behçet's disease. Ocul Immunol Inflamm 2012, 20:193-197.
72. Davatchi F., Sadeghi Abdollahi B., Tehrani Banihashemi A., Shahram F., Nadji A., Shams H., et al. Colchicine versus placebo in Behçet's disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol 2009, 19:542-549.
73. Sun A., Wang Y.P., Chia J.S., Liu B.Y., Chiang C.P. Treatment with levamisole and colchicine can result in a significant reduction of IL-6, IL-8 or TNF-alpha level in patients with mucocutaneous type of Behcet's disease. J Oral Pathol Med 2009, 38:401-405.
74. Portincasa P., Scaccianoce G., Palasciano G. Familial Mediterranean fever: a fascinating model of inherited autoinflammatory disorder. Eur J Clin Invest 2013, 43:1314-1327.
75. Dinarello C.A., Wolff S.M., Goldfinger S.E., Dale D.C., Alling D.W. Colchicine therapy for familial Mediterranean fever. A double-blind trial. N Engl J Med 1974, 291:934-937.
76. Ben-Chetrit E. Familial Mediterranean fever (FMF) and renal AA amyloidosis-phenotype-genotype correlation, treatment and prognosis. J Nephrol 2003, 16:431-434.
77. Kallinich T., Haffner D., Niehues T., Huss K., Lainka E., Neudorf U., et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 2007, 119:e474-e483.
78. Imazio M., Bobbio M., Cecchi E., Demarie D., Pomari F., Moratti M., et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med 2005, 165:1987-1991.
79. Imazio M., Bobbio M., Cecchi E., Demarie D., Demichelis B., Pomari F., et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation 2005, 112:2012-2016.
80. Imazio M., Brucato A., Cemin R., Ferrua S., Belli R., Maestroni S., et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med 2011, 155:409-414.
81. Imazio M., Belli R., Brucato A., Cemin R., Ferrua S., Beqaraj F., et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicenter, double-blind, placebo-controlled, randomized trial. Lancet 2014, 383:2232-2237.
82. Imazio M., Brucato A., Cemin R., Ferrua S., Maggiolini S., Beqaraj F., et al. A randomized trial of colchicine for acute pericarditis. N Engl J Med 2013, 369:1522-1528.
83. Imazio M., Belli R., Brucato A., Ferrazzi P., Patrini D., Martinelli L., et al. COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicenter, randomized, double-blind, placebo-controlled trial. Eur Heart J 2010, 31:2049-2054.
84. Imazio M., Belli R., Brucato A., Ferrazzi P., Patrini D., Martinelli L., et al. Rationale and design of the COlchicine for Prevention of the Post-pericardiotomy Syndrome and Post-operative Atrial Fibrillation (COPPS-2 trial): a randomized, placebo-controlled, multicenter study on the use of colchicine for the primary prevention of the postpericardiotomy syndrome, postoperative effusions, and postoperative atrial fibrillation. Am Heart J 2013, 166:13-19.
85. Kuo I.F., Pearson G.J., Koshman S.L. Colchicine for the primary and secondary prevention of pericarditis: an update. Ann Pharmacother 2009, 43:2075-2081.
86. Imazio M., Brucato A., Forno D., Ferro S., Belli R., Trinchero R., et al. Efficacy and safety of colchicine for pericarditis prevention. Systematic review and meta-analysis. Heart 2012, 98:1078-1082.
87. Imazio M., Brucato A., Markel G., Cemin R., Trinchero R., Spodick D.H., et al. Meta-analysis of randomized trials focusing on prevention of the postpericardiotomy syndrome. Am J Cardio 2011, 108:575-579.
88. Lotrionte M., Biondi-Zoccai G., Imazio M., Castagno D., Moretti C., Abbate A., et al. International collaborative systematic review of controlled clinical trials on pharmacological treatments for acute pericarditis and its recurrences. Am Heart J 2010, 160:662-670.
89. Alam M., Kayani W.T., Bandeali S.J., Shahzad S.A., Huang H.D., Virani S.S., et al. Impact of Colchicine on pericardial inflammatory syndromes-an analysis of randomized controlled trials. Int J Cardiol 2012, 161:59-62.
90. Maisch B., Seferović P.M., Ristić A.D., Erbel R., Rienmüller R., Adler Y., et al. Guidelines on the diagnosis and management of pericardial diseases executive summary; the Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J 2004, 25:587-610.
91. Nidorf S.M., Eikelboom J.W., Budgeon C.A., Thompson P.L. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013, 61:404-410.
92. Deftereos S., Giannopoulos G., Raisakis K., Kossyvakis C., Kaoukis A., Panagopoulou V., et al. Colchicine treatment for the prevention of bare metal stent restenosis in diabetic patients. J Am Coll Cardiol 2013, 61:1679-1685.
93. Raju N.C., Yi Q., Nidorf M., Fagel N.D., Hiralal R., Eikelboom J.W., et al. Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. J Thromb Thrombolysis 2012, 33:88-94.
94. Deftereos S., Giannopoulos G., Panagopoulou V., Bouras G., Raisakis K., Kossyvakis C., et al. Anti-Inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. JACC Heart Fail 2014, 2:131-137.
95. Morgan T.R., Weiss D.G., Nemchausky B., Schiff E.R., Anand B., Simon F., et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival. Gastroenterology 2005, 128:882-890.
96. Kershenobich D., Vargas F., Garcia-Tsao G., Perez Tamayo R., Gent M., Rojkind M., et al. Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 1988, 318:1709-1713.
97. Rambaldi A., Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst Rev 2005, 18:CD002148.
98. Muntoni S., Rojkind M., Muntoni S. Colchicine reduces procollagen III and increases pseudocholinesterase in chronic liver disease. World J Gastroenterol 2010, 16:2889-2894.
99. Kaplan M.M., Bonder A., Ruthazer R., Bonis P.A. Methotrexatein patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid. Dig Dis Sci 2010, 55:3207-3217.
100. Fontes V., Machet L., Huttenberger B., Lorette G., Vaillant L. Recurrent aphthous stomatitis: treatment with colchicine. An open trial of 54 cases. Ann Dermatol Venereol 2002, 129:1365-1369.
101. Pakfetrat A., Mansourian A., Momen-Heravi F., Delavarian Z., Momen-Beitollahi J., Khalilzadeh O., et al. Comparison of colchicine versus prednisolone in recurrent aphthous stomatitis: a double-blind randomized clinical trial. Clin Invest Med 2010, 33:E189-E195.
102. Criado R.F., Criado P.R., Martins J.E., Valente N.Y., Michalany N.S., Vasconcellos C., et al. Urticaria unresponsive to antihistaminic treatment: an open study of therapeutic options based on histopathologic features. J Dermatolog Treat 2008, 19:92-96.
103. Lawlor F., Black A.K., Ward A.M., Morris R., Greaves M.W. Delayed pressure urticaria, objective evaluation of a variable disease using a dermographometer and assessment of treatment using colchicine. Br J Dermatol 1989, 120:403-408.
104. van der Zee H.H., Prens E.P. The anti-inflammatory drug colchicine lacks efficacy in hidradenitis suppurativa. Dermatology 2011, 223:169-173.
105. Safarinejad M.R. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study. Int J Impot Res 2004, 16:238-243.
106. Fiorucci E., Lucantoni G., Paone G., Zotti M., Li B.E., Serpilli M., et al. Colchicine, cyclophosphamide and prednisone in the treatment of mild-moderate idiopathic pulmonary fibrosis: comparison of three currently available therapeutic regimens. Eur Rev Med Pharmacol Sci 2008, 12:105-111.